Sangamo Therapeutics (NASDAQ: SGMO) is a genomic medicine company headquartered in Richmond, California, focused on translating ground-breaking science into genomic medicines using zinc finger nucleases (ZFNs), zinc finger protein transcription factors (ZFP-TFs), and adeno-associated virus (AAV) delivery. Sangamo's clinical-stage pipeline includes giroctocogene fitelparvovec (hemophilia A gene therapy, partnered with Pfizer) and isavufermin or SAR445136 (alpha-1 antitrypsin deficiency, partnered with Sanofi). The company is also developing preclinical in vivo genome-editing programs and ex vivo gene-edited cell therapies.
Company Info
Recent News
Sangamo Therapeutics filed for bankruptcy after three decades in genomic medicine, with Eli Lilly and Astellas emerging as stalking horse bidders for its Fabry gene therapy and other key assets.
Leadership Team
Chief Executive Officer and President
Careers & Job Openings